WO2004007020A2 - Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs - Google Patents
Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs Download PDFInfo
- Publication number
- WO2004007020A2 WO2004007020A2 PCT/US2003/021655 US0321655W WO2004007020A2 WO 2004007020 A2 WO2004007020 A2 WO 2004007020A2 US 0321655 W US0321655 W US 0321655W WO 2004007020 A2 WO2004007020 A2 WO 2004007020A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- breast
- energy
- treatment
- tissue
- ofthe
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
Definitions
- the present invention generally relates to a minimally invasive method for administering focused energy such as adaptive microwave phased array hyperthermia for treating ductal and glandular carcinomas and intraductal hyperplasia as well as benign lesions such as i ⁇ broadenomas and cysts in compressed breast tissue.
- focused energy such as adaptive microwave phased array hyperthermia
- the method according to the invention may be used to treat healthy tissue containing undetected microscopic pathologically altered cells of high-water content to prevent the occurrence of or the recurrence of cancerous, pre-cancerous or benign breast lesions.
- Tl 0.-2 cm
- T2 2-5 cm
- the entire breast is at risk and often is treated with breast-conserving surgery combined with full-breast irradiation to destroy any possible microscopic (not visible to the human eye without the aid of a microscope or mammography) cancer cells in the breast tissue
- EIC intraductal component
- Over 800,000 breast needle biopsies of suspicious lesions are performed annually in the United States with approximately 180,000 cases of cancer detected, the rest being nonmalignant such as fibroadenomas and cysts.
- the affected breast contains two or more tumor masses distributed within the breast, known as multi-focal cancer, and again the heating field must reach widely separated regions of the breast.
- Locally advanced breast carcinomas known as T3 (Smart et al., A Cancer Journal for Clinicians, Vol. 47, pp. 134-139, 1997) can be 5 cm or more in size and are often treated with mastectomy.
- Pre-operative hyperthermia treatment of locally advanced breast cancer may shrink the tumor sufficiently to allow a surgical lumpectomy procedure to be performed - similar to the way pre-operative chemotherapy is currently used.
- Pre- operative hyperthermia treatment of locally advanced breast cancer may destroy the tumor completely, eliminating the need of any surgery.
- microwave energy can preferentially heat high-water content tissues such as breast tumors and cysts, compared to the heating that occurs in low-water content tissue such as fatty breast tissue.
- hyperthermia elevated temperature
- Many clinical studies have established that hyperthermia (elevated temperature) induced by electromagnetic energy absorption in the microwave band, significantly enhances the effect of radiation therapy in the treatment of malignant tumors in the human body (Valdagni, et al., International Journal of Radiation Oncology Biology Physics, Vol.28, pp. 163- 169, 1993; Overgaard et al., International Journal of Hyperthermia, Vol. 12, No. 1, pp. 3-20, 1996; Vernon et al., International Journal of Radiation Oncology Biology Physics, Vol.
- Radio-resistant cells such as S- phase cells can be killed directly by elevated temperature (Hall, Radiobiology for the Radiologist, 4 th Edition, JB Lippincott Company, Philadelphia, pp. 262-263, 1994; Perez and Brady, Principles and Practice of Radiation Oncology, Second Edition, JB Lippincott Company, Philadelphia, pp. 396-397, 1994).
- Hyperthermia treatments with microwave radiating devices are usually administered in several treatment sessions, in which the malignant tumor is heated to about 43° C for about 60 minutes. It is known that the amount of time to kill tumor cells decreases by a factor of two for each degree increase in temperature above about 43° C (Sapareto, et al., International Journal of Radiation Oncology Biology Physics, Vol. 10, pp. 787-800, 1984). Thus, a 60-minute treatment at 43° C can be reduced to only about 15 minutes at 45° C, which is often referred to as an equivalent dose (t 43° c equivalent minutes). It has also been clinically established that thermotherapy enhances the effect of chemotherapy (Falk and Issels, 2001).
- the specific absorption rate (SAR) in tissue is a common parameter used to characterize the heating of tissue.
- the SAR is proportional to the rise in temperature over a given time interval, and for microwave energy the SAR is also proportional to the electric field squared times the tissue electrical conductivity.
- the units of absolute SAR are watts per kilogram.
- Non-coherent-array or non-adaptive phased array hyperthermia treatment systems typically can heat superficial tumors, but are restricted in their use for heating deep tumors or deep tissue, because they tend to overheat intervening superficial tissues, which can cause pain and/or burning.
- the first published report describing a non-adaptive phased array for deep tissue hyperthermia was a theoretical study (von Hippel, et al., Massachusetts Institute of Technology, Laboratory for Insulation Research, Technical Report 13, AD-769 843, pp. 16-19, 1973).
- U.S. Patent No. 3,895,639 to Rodler describes two-channel and four-channel non-adaptive phased array hyperthermia circuits.
- An adaptive phased array hyperthermia system uses E-field feedback measurements to focus its microwave energy on deep tissue while simultaneously nullifying any energy that might overheat surrounding healthy body tissue.
- Pre- clinical studies indicate that adaptive microwave phased arrays have the potential for delivering deep heat while sparing superficial tissues from excessive temperatures in deep torso (Fenn, et al., International Journal of Hyperthermia, Vol. 10, No.2, March- April, pp. 189-208, 1994; Fenn et al, The Journal of Oncology Management, Vol. 7, number 2, pp. 22-29, 1998) and in breast (Fenn, Proceedings of the Surgical Applications of Energy Sources Conference, 1996; Fenn et al., International Journal of Hyperthermia, Vol. 15, No. 1, pp. 45-61, 1999; Gavrilov et al., International Journal of Hyperthermia, Vol. 15, No. 6, pp. 495-507, 1999).
- Noninvasive multiple applicator adaptive microwave phased arrays with invasive and noninvasive electric field probes can be used for producing an adaptively focused beam at the tumor position with adaptive nulls formed in healthy tissues as described in U.S. Pat Nos. 5,251,645, 5,441,532, 5,540,737, and 5,810,888, all of which are incorporated herein by reference.
- a focused microwave radiation beam is concentrated at the tumor with minimal energy delivered to surrounding healthy tissue.
- a temperature-sensing feedback probe (Samaras et al., Proceedings of the 2 nd International Symposium, Essen, Germany, June 2-4, 1977, Urban & Schwarzenberg, Baltimore, 1978, pp. 131 - 133) is inserted into the tumor, however, it is often difficult to accurately place the probe in the tumor.
- An additional difficulty occurs in delivering hyperthermia to carcinoma spread throughout the ductal or glandular tissues ofthe breast, because of a lack of a well defined target position for the temperature-sensing feedback probe.
- the Assignee ofthe instant invention's method for heating cancerous conditions ofthe breast which comprises the steps of inserting an E-field probe sensor in the breast, monitoring temperatures ofthe skin surface, orienting two microwave applicators on opposite sides ofthe breast, setting the initial microwave power and phase delivered to each microwave applicator in order to focus the field at the inserted E-field sensor, adjusting the microwave power to be delivered to the breast based on the monitored skin temperatures, and monitoring the microwave energy dose delivered to the breast being treated and completing the treatment when a desired total microwave energy dose has been delivered by the microwave applicators.
- the above method by the Assignee of the instant invention has application in situations such as when there is no well-defined position to place the temperature feedback sensor, or when it is desirable to avoid inserting a temperature probe into the breast tissue. Only a single minimally invasive E-field sensor is required in the preferred method taught by the Assignee.
- this method can destroy a significant portion of the breast cancer cells and shrink the tumor or lesion (i.e., thermal downsizing to e.g., 2 - 3 cm) thereby replacing a surgical mastectomy with a surgical lumpectomy.
- the entire advanced breast cancer lesion can be destroyed and no surgery may be required.
- the Assignee's method may destroy all of the breast cancer cells or benign lesions with heat (i.e., a thermal lumpectomy) thereby avoiding a surgical lumpectomy.
- the method can be used to enhance radiation therapy or for targeted drug delivery with thermosensitive liposomes as described in U.S. Pat. No. 5,810,888 and/or targeted gene therapy delivery.
- the assignee's method maybe used with a recently developed temperature sensitive liposome formulation with chemotherapy agents such as doxorubicin as described in U.S. Pat. No. 6,200,598 "Temperature Sensitive Liposomal Formulation," March 13, 2001 to Needham, in which drug agents are released at temperatures of approximately 39 to 45 degrees Celsius.
- the assignee's method described above destroys the cancerous cells while sparing the normal glandular, ductal, connective, and fatty tissue ofthe breast.
- a thermal lumpectomy according to the invention avoids damage to such healthy tissue and is a breast conservation technique.
- focussing energy in general, may be used to heat and ablate an area of tissue.
- the focused energy may include electromagnetic waves, ultrasound waves or waves at radio frequency. That is, any energy that can be focused to heat and ablate an area of tissue.
- the method according to the invention may include the steps of inserting an E-field probe sensor to an appropriate depth in the organ tissue, monitoring temperatures of the skin surface adjacent the organ, positioning two or more energy applicators around the organ, setting the initial power level delivered to each energy applicator, setting the initial relative phase delivered to each energy applicator to focus the energy at the E-field probe positioned in the organ tissue, delivering energy to the two or more energy applicators to selectively irradiate the organ tissue with focused energy and treat at least one of cancerous and benign conditions of the organ, adjusting the level of power to be delivered to each energy applicator during treatment based on the monitored skin temperatures, monitoring the energy delivered to the energy applicators, determining total energy delivered to the energy applicators and displaying the total energy in real time during the treatment, and completing the treatment when the desired total energy dose has been delivered by the
- a preferred method for treating cancerous or benign conditions of an organ by selective irradiation ofthe organ tissue with energy may include the steps of injecting a substance that enhances heating to an appropriate depth in the organ tissue, monitoring temperatures of the skin surface adjacent the organ, positioning at least one energy applicator about the organ, setting the initial power level delivered to each at least one energy applicator, delivering energy to the at least one energy applicator to selectively irradiate the organ tissue with energy and treat at least one of cancerous and benign conditions ofthe organ, adjusting the level of power to be delivered to each at least one energy applicator during treatment based on the monitored skin temperatures, monitoring the energy delivered to the at least one energy applicator, determining total energy delivered to the at least one energy applicator and displaying the total energy in real time during the treatment, and completing the treatment when the desired total energy dose has been delivered by the at least one energy applicator to the organ.
- the method according to the invention may be achieved with a single applicator and may be any energy that can be focussed on the cancerous or benign conditions ofthe organ.
- microwave absorbing pads and metallic shielding are attached to microwave thermotherapy applicators and to the breast compression paddles. These safety precautions added to the Assignee's method reduce the electric-field intensity and temperature outside the primary microwave applicator aperture field in the vicinity ofthe base ofthe breast, chest wall region, and head and eyes during adaptive phased array thermotherapy in compressed breast tissue for breast tumor (malignant or benign) treatment.
- adaptive microwave phased array thermotherapy can be used as a heat-alone treatment for early-stage breast cancer.
- adaptive microwave phased array thermotherapy can be used in combination with a chemotherapy regimen and/or gene based modifiers for treatment ofthe primary breast tumor in locally advanced breast cancer.
- the breast thermotherapy heat-alone treatment can be used as a pre-surgical tool to reduce the rate of second or third incisions (additional surgery) for lumpectomy patients.
- An additional use of adaptive microwave thermotherapy can be in improved breast cancer prevention in which thermotherapy is used with Tamoxifen or other antiestrogen drug for blocking estrogen from binding to the estrogen receptors of breast carcinomas and for direct cancer cell kill by heat.
- Fig. 1 is a detailed lateral view ofthe female breast
- Fig. 2 shows examples ofthe progression of ductal carcinomas and lobular carcinomas in the ductal and glandular tissues ofthe breast
- Fig. 3 shows the measured values of dielectric constant and electrical conductivity for normal breast tissue and breast tumor for three different studies.
- the study labeled B (Burdette) was for measurements through the breast skin which accounts for the differences between the other studies, denoted C and J;
- Fig 4 shows the measured water content of breast fat, glandular/connective tissue, benign Fibroadenoma, and breast carcinoma (from Campbell and Land 1992);
- Fig. 5 shows the system according to the invention for heating the breast under compression;
- Fig. 6 shows the patient in a prone position with the breast compressed and an E-field probe inserted at the desired focal depth in the breast;
- Fig. 7 shows the calculated focal microwave energy as a function of compressed breast tissue thickness
- Fig. 8 shows a three-dimensional view of the computer simulated dual- opposing microwave waveguide applicators used in heating the breast;
- Fig. 9 shows a calculated side view ofthe 915 MHz specific absorption rate (SAR) heating pattern in homogeneous normal breast tissue with central focus
- Fig. 10 shows a calculated top view of the 915 MHz SAR heating pattern in homogeneous normal breast tissue with central focus
- Fig. 11 shows a calculated end view ofthe 915 MHz SAR heating pattern in homogeneous normal breast tissue with central focus
- Fig. 12 shows a calculated top view of the 915 MHz SAR heating pattern when there are two simulated breast tumors, each with a diameter of 1.5 cm, spaced 5 cm apart.
- the 50% SAR contours are aligned with the tumors indicative of selective heating;
- Fig. 13 shows a calculated linear cut of the 915 MHz SAR heating pattern (through the central plane of Figure 12) when there are two simulated breast tumors, each with a diameter of
- the SAR has sharp peaks that are aligned with the tumors indicative of selective heating
- Figure 14 illustrates a breast thermotherapy system according to the invention with added safety features including microwave absorbing pad on top of waveguide applicator and metallic shield covering top section of waveguide aperture;
- Figure 15 is a side view showing a simple T-shaped breast phantom with microwave absorbing pads, metallic shielding, air gaps, and combined E-field focusing and temperature probes;
- Figure 16 is a side view showing a breast-shaped phantom with microwave absorbing pads, metallic shielding, air gaps, and combined E-field focusing and temperature probes;
- Figure 17 shows a compression paddle with a rectangular shaped window in the vertical surface and a microwave absorbing pad attached to the top surface ofthe paddle;
- Figure 18 is a side view of waveguide applicators with metallic shielding added to the upper portion of the compression paddles on the surface facing away from the breast skin;
- Figure 19 is a graph showing measured temperature versus time for the simple T-shaped phantom heated by the adaptive phased array applicators, without shielding and absorbing pads;
- Figure 20 is a graph showing measured temperature versus time as the simple T-shaped phantom heated by the adaptive phased array applicators with shielding and absorbing pads.
- FIG. 1 A detailed lateral view of the female breast is shown in Figure 1 (Mammography - A User's Guide, National Council on Radiation Protection and Measurements, NCRP Report No. 85, 1 August 1987, p.6).
- the amount of glandular and fatty tissue within the breast can vary widely, from primarily fatty tissue to extremely dense glandular tissue.
- Breast cancer cells which are high-water content cells, usually form within the lactiferous ducts and glandular tissue lobules as depicted in Figure 2 (adapted from Dr. Susan Love's Breast Book, Addison Wesley, Mass., 1990, pp. 191-196).
- intraductal hyperplasia The first indication of abnormal cell growth within the duct is referred to as intraductal hyperplasia, followed by intraductal hyperplasia with atipia.
- intraductal carcinoma in situ DCIS
- pre-cancers the condition is known as pre-cancers.
- invasive ductal cancer Cancer forms in the same way in the glandular lobules of the breast. All of the above cells are often cited as being high-water content with the exception of pure fat tissue (low-water content) and pure glandular/connective tissue (low to medium-water content) within the breast.
- Microwave radiation in the Industrial, Scientific, Medical (ISM) band 902 to 928 MHz is commonly used in commercial clinical hyperthermia systems, and is the primary frequency band considered here.
- Four main articles are: 1) Chaudhary et al., Indian Journal of Biochemistry and Biophysics, Vol. 21 , pp. 76-79, 1984; 2) Joines et al., Medical Physics, Vol. 21 , No. 4, pp. 547-550, 1994; 3) Surowiec et al., IEEE Transactions on Biomedical Engineering, Vol. 35, No. 4, pp.
- the article by Surowiec et al. has detailed information on selected glandular, ductal, fatty and cancerous tissues, but they only measured the parameters in the range 20 kHz to 100 MHz. It is possible to estimate the electrical properties of breast tissues at 915 MHz from data measured at 100 MHz. Applicants are not aware of any measured dielectric parameter data on pure ductal and glandular breast tissue for the frequency of interest, namely 915 MHz.
- the article by Campbell and Land has measured dielectric parameter data at 3.2 GHz, and the percent water content of breast fat, glandular and connective tissue, benign tumors (including fibroadenomas), and malignant tumors. Their measured data of percent water content can be used to assess the relative heatability of breast tissues, that is, higher water content tissues heat faster than lower water content tissues.
- the range of values for measured water content (by weight) is as follows: breast fat (11 to 31%), glandular and connective tissue (41 to 76%), benign tumors (62 to 84%), and malignant tumors (66 to 79%) where selected values are depicted in Figure 4.
- Tissue electrical conductivity is a primary controlling parameter for tissue heating with microwave energy.
- Tissue electrical conductivity is also referred to as tissue ionic conductivity with units of Siemens per meter.
- Electrical conductivity is a function of the tissue properties primarily the water content, ion content, and temperature (F.A. Duck, Physical Properties of Tissue, Academic Press, 1990, Chapter 6, pp. 167-223). The electrical conductivity increases as the water content, ion content, and temperature of the tissue increases. For example, physiological saline has a higher ionic conductivity than pure water.
- Warm saline has a higher ionic conductivity than cool saline.
- Invasive or infiltrating breast cancer cells are reported as being moderately to poorly differentiated, meaning they increasingly lose the ability to function as normal cells. As cancer cells lose their functionality they can swell in size and absorb more water thereby increasing the percent water content.
- Ions in the water of a cancer cell play a significant role in the cell's ionic conductivity. Ions are electrically charged particles either positive or negative.
- the important ions in tissues include potassium (K+), calcium (Ca2+), sodium (Na+), and chlorine (C1-).
- the calcium ion has two less electrons than protons and is positively charged (2+). Calcium can attract and hold two chlorine (C1-) ions. Potassium can attract and hold only one chlorine (C1-) ion.
- the calcium and chloride ions in calcium chloride (CaC12) will dissociate or separate and increase in mobility when dissolved in water that increases the ionic conductivity ofthe water solution.
- Tightly clustered calcium deposits appearing on mammograms are often associated with carcinomas (S.M. Love, Dr. Susan Love's Breast Book, Third Edition, Persus Publishing, 2000, pp. 130-131).
- a tiny cluster of microcalcifications in a milk duct is usually attributed to precancer. Big chunks of calcium are usually associated with a benign lesion such as a fibroadenoma.
- Some of the calcifications appearing in the breast are from calcium leaving the bone, traveling through the blood stream and randomly deposited within the breast. [027]
- the proteins and ionic components in breast cyst fluid have been measured (B.
- Type I high levels of potassium (K+) and medium levels of sodium (Na+) and chloride (C1-),
- Type II high levels of potassium (K+) and sodium (Na+) and medium levels of chloride (C1-), and
- Type HI high levels of sodium (Na+), medium levels of chloride (C1-), and low levels of potassium (K+).
- Na+ sodium
- C1- medium levels of chloride
- K+ potassium
- cysts There are several types of cysts: gross cysts forming palpable tumors, cysts containing inspissated (thickened) milk - so called “galactoceles", cysts evolving from duct ectasia, cysts resulting from fat necrosis, cysts associated with intraductal papilloma - so called “papillary cystadenoma, and cysts induced by the administration of estrogen. Gross (very large) cysts can develop quickly and obtain a moderate size that persists, while some decrease in size and even disappear with time. A considerable portion of gross cysts are discovered in the premenstrual or menstrual phase and enlarge rapidly and become painful and tender.
- Gross cysts are sometimes associated with signs of acute inflammation, pain, tenderness, and slight redness of the overlying skin. Following needle aspiration of the cyst fluid, signs of inflammation promptly subside. After aspiration is completed, only a fibrosed cyst wall remains. However, cyst fluid escaping into the surrounding breast tissue can produce acute irritation. Gross cysts are most common in the age group between 30 and 54 years, or about 95% of cases. The more extensively a surgeon operating for cystic conditions explores the breast, more cysts are likely to be found. [029] Fibroadenomas (very common benign lumps, also called fibroids) are smooth and hard and can vary in size from 5 mm up to about 5 cm.
- Benign fibrosis tumors The median water content for one patient (age 26) in the Campbell and Land study was 65.5%, suggestive of high-water content.
- Fibrosis refers to the formation of fibrous tissue that can occur as a reparative or reactive process.
- Fibrous breast disease is a special type of fibrosis that suppresses and obliterates both the acini ofthe lobules and the mammary ducts in a localized portion of the breast, and forms a palpable tumor.
- Fibrosis is abnormally firm (but not as hard as a carcinoma) and usually requires a local excision; however, the limits ofthe disease are often not well defined since the lesion shape is irregularly discoid rather than rounded like a cyst.
- Benign fibroadrosis tumors The median water content for one patient (age 27) in the Campbell and Land study was 73.5% suggestive of high-water content.
- Benign epitheliosis (also known as papillomatosis) tumors The median water content for one patient (age 40) in the Campbell and Land study was 61% suggestive of high-water content.
- Papillomatosis is a papillary proliferation of the ductal epithelium which partly fills up smaller ducts and to a degree distends them. Papillomatosis is usually microscopic and appears often with cystic disease, tumor adnosis, multiple papilloma, or some other tumor-forming lesion.
- Benign adnosis tumors The median water content for one patient (age 43) in the Campbell and Land study was 38%, suggestive of low-water content. Benign adnosis is a proliferation of the acini of the mammary lobules appearing both microscopically and as a definite tumor. These tumors (benign adnosis) may not heat significantly compared to surrounding normal breast tissue, but only one data sample was measured and may not be representative of other benign adnosis tumors.
- benign lesions such as cysts, fibroadenomas, fibrosis, fibroadrosis, and epitheliosis (also known as papillomatosis) appear to be high-water and/or high-ionic content and should be readily heated by microwave energy. Benign adnosis lesions may not heat as rapidly as cysts having high-water and/or high-ionic content; however, it is unclear as the data, upon which this is based, is limited to a single patient.
- the Assignee's inventive method can destroy a significant portion ofthe breast cancer cells with heat alone or with heat in combination with chemotherapy.
- shrinking the tumor or lesion i.e., thermal downsizing to e.g., 2 - 3 cm
- a surgical mastectomy i.e., thermal downsizing to e.g., 2 - 3 cm
- the entire advanced breast cancer lesion can be destroyed (that is, a thermal mastectomy or a thermochemo mastectomy) and no surgery may be required.
- early-stage breast cancer or small breast lesions may be destroyed with the Assignee's inventive method.
- Thermotherapy may be used as a heat-alone treatment prior to an initial (or second or third) lumpectomy to reduce the need for re-excision (additional surgery), which occurs when positive margins (cancerous cells) are detected in a lumpectomy specimen.
- re-excision additional surgery
- Around 30%> of lumpectomy specimen have positive margins that require a second incision. Since the method according to the invention heats tissue from the outside in to the target area (in contrast to RF ablation, which heats from the inside out), the method according to the invention addresses the margins.
- thermotherapy treatment according to the invention can be applied prior to surgery with the expectation that cancer cells in the margins are ablated.
- the initial surgery lumpectomy
- the area around the excised tissue (margins) is tested and a reduction in the cancer in the margins is expected thereby avoiding the need for a second (or third) incision.
- the thermotherapy treatment according to the invention theoretically could be employed as a thermo- lumpectomy, which replaces the invasive lumpectomy surgical procedure.
- the amount of cancer in the breast may be significantly reduced or destroyed in its entirety by the thermotherapy treatment according to the invention.
- thermotherapy treatment according to the invention could be used in combination with gene based modifiers to benefit patients that have abnormal (mutant) genes in their tissue, such as BRCAl, BRCA2, or other genes.
- abnormal genes has been shown as increasing the risk of that patient getting cancer, and thus the ablation of these genes should reduce the patient's risk of getting cancer.
- Either a heat-alone thermotherapy treatment or thermotherapy with chemotherapy and/or gene based modifiers combined with heat should reduce breast cancer recurrence by destroying any cancerous cells in the margins thereby providing tissue free of cancer, or to destroy or repair mutant genes responsible for cancer and other diseases.
- the method can be used in combination with thermosensitive liposomes as described in U.S. Pat.
- No.5,810,888 and/or targeted gene therapy delivery for treating breast lesions to enhance radiation therapy and/or for targeted drug delivery to aid in the destruction of cancerous or abnormal cells in the margins.
- Breast cancer begins within the breast ducts and then invades outwards into surrounding breast tissues and subsequently spreads outside the breast via the lymphatic and vascular (blood) systems.
- a thermotherapy treatment alone or in combination with chemotherapy and/or gene based modifiers should reduce breast cancer recurrence within the breast or other organs by killing cancer cells or mutant genes within the lymphatic and vascular systems ofthe breast.
- the heat-treatment therapy according to the invention could be used alone or in combination with chemotherapy and/or gene based modifiers to pretreat other organs, such as the prostate, liver, ovaries, etc., in which the presence of abnormal or mutant genes may lead to a higher occurrence of cancer.
- the use of heat- alone thermotherapy or thermotherapy with chemotherapy and/or gene based modifiers may be beneficial when there is a presence of atypical cells in an organ, as determined by ductal lavage or other diagnostic technologies.
- thermotherapy treatments higher equivalent thermal dose and higher breast tumor temperatures may be required to complete heat-alone ablation of breast carcinomas.
- Tumor temperatures in the range of 49 to 50 degrees C or up to 55 degrees C may be required for complete ablation of tumors with an equivalent thermal dose of 400 minutes and a microwave energy dose up to 500 kilojoules.
- thermal and microwave energy doses it may be necessary to provide additional safety methods for protecting the breast skin and adj acent healthy tissues such as the chest wall region from any heat damage.
- Ductal carcinoma in situ also known as DCIS or intraductal carcinoma
- DCIS Ductal carcinoma in situ
- a needle biopsy diagnosis of DCIS may underestimate the presence ofthe invasive disease due to a sampling error. As a result of the sampling error, an accurate diagnosis of the disease progress can be difficult to obtain.
- the major goal of any pathologic evaluation of a DCIS patient is to determine the level of risk of subsequent invasion so that proper treatment is offered and possible over- or under-treatment is avoided.
- breast-conserving surgery can be accomplished with an acceptable cosmetic result.
- long-term follow-up of DCIS patients treated with complete surgical excision and radiation therapy shows that as many as 19% or more of DCIS patients experience a local recurrence, with up to 50% of these local recurrences being invasive.
- the recurrence rate can be as high as 26%.
- thermotherapy one or two treatments
- the cost for thermotherapy is expected to be less than the cost of radiation therapy, thus resulting in savings to the overall health cost.
- Thermotherapy may also be given several times with conventional radiation therapy for increased effectiveness in destroying ductal carcinoma in-situ (DCIS).
- heat and chemotherapy could be used together to destroy and/or downsize the primary breast cancer thereby converting mastectomy candidate patients to a more conservative lumpectomy surgery.
- patients may require pre-operative chemotherapy as part of their breast cancer treatment regimen. This would entail four cycles or courses of chemotherapy administered in accordance with standard pre- operative and post-operative chemotherapy delivery as in NSABP B-l 8 (Fisher et al., 1997, J. Clinical Oncology, vol. 15(7), pages 2483-2493; and Fisher et al, 1998, J. Clinical Oncology, vol. 16(8), pages 2672-2685).
- a focused microwave phased array thermotherapy session can be administered on the same day as the administration ofthe first, second, and third course of pre-operative AC chemotherapy or within 36 hours of administration of AC chemotherapy.
- the remaining (fourth) cycle of AC chemotherapy would then be administered without thermotherapy prior to surgery in order to allow sufficient time for any skin related thermotherapy effects to resolve (for example, skin blisters).
- thermotherapy could be applied prior to chemotherapy to shrink the breast tumor before chemotherapy is infused. It is known that pre-operative AC chemotherapy will cause approximately 80% of breast cancer tumors to have some shrinkage.
- thermotherapy Tumor shrinkage is usually seen after the first course of AC chemotherapy is completed and is typically observed by ultrasound imaging about 21 days after the first course of AC chemotherapy is completed. There is not enough data to prove that the combination of thermotherapy and AC chemotherapy will cause tumors to shrink as much as AC chemotherapy by itself. Thus, in another embodiment, to see significant shrinkage it may be desirable to administer at least one dose of chemotherapy prior to administering thermotherapy. If three thermotherapy courses are used, thermotherapy will be administered on the same day or within 36 hours of the administration of the second, third, and fourth course of pre-operative chemotherapy. If two thermotherapy courses are used, thermotherapy could be administered on the same day or within 36 hours of the administration of the second and third course, or third and fourth course of pre- operative chemotherapy, or second and fourth course of chemotherapy.
- thermotherapy is applied so that tumor temperatures reach between approximately 43 - 46 degrees C, and tumors receive equivalent thermal doses of approximately 50 to 100 minutes per treatment, and microwave energy doses of approximately 100 to 300 kilojoules.
- the decision is made, based on the same guidelines used when the patient was enrolled in the study (that is, size and location of tumor, size of breast, patient health, and patient age), whether the patient will receive a mastectomy or a partial mastectomy (lumpectomy) for breast conservation.
- the usual standard of care including drugs and radiation
- Thermotherapy and Drug Therapy for primary breast cancer prevention [048]
- the current standard of care for breast cancer prevention is either prophylactic mastectomy (surgical removal ofthe breasts) or Tamoxifen treatment.
- Tamoxifen and other drugs like raloxifene
- 13175 participants received either Tamoxifen (20 mg daily for 5 years) or placebo.
- Overall a 49% reduction in the risk of invasive breast carcinomas was observed in the Tamoxifen (trade name Nolvadex) group (Fisher B., et al.
- thermotherapy added to a Tamoxifen prevention treatment may further increase the reduction in the risk of invasive breast carcinomas by increasing the amount of blockage of estrogen to the estrogen receptors of breast carcinomas.
- the amount of blockage of estrogen may be achieved by damaging or modifying the estrogen receptors and/or by killing breast carcinomas directly with the heat.
- thermotherapy patients in the thermotherapy and Tamoxifen arm would receive the standard dose of Tamoxifen (20 mg per day for 5 years) and thermotherapy at regular intervals during the same 5-year period.
- the target region would simply be the upper portion ofthe breast where approximately 70% of all breast cancers occur as measured from the nipple to the upper base ofthe breast (Mammography - A User's Guide, NCRP Report No. 85, National Council on Radiation Protection and Measurements, Bethesda, p. 7, 1987).
- breast compression would be in the cranial-caudal (head-to-toe) position and the E-field focusing probe would be positioned approximately 0.5 to 1.5 cm toward the cranial side ofthe breast (as measured from the central breast depth).
- a microwave energy dose of approximately 180 kilojoules (100 Watts total for 30 minutes) would be administered to the breast in each of multiple treatments spaced at approximately one-year intervals during the administration of Tamoxifen.
- a control group for this hypothetical clinical trial would include patients receiving Tamoxifen treatment only.
- An initial microwave power for each ofthe two channels maybe approximately 50 Watts, which has been verified to be a safe power level based on the treatment of approximately 35 breast cancer patients in Celsion Corporation's Phase I and Phase II adaptive phased array breast thermotherapy clinical studies. Skin temperature sensors may be monitored and the microwave power ofthe two channels would be adjusted in order to keep skin temperatures below about 41 degrees Celsius during the thermotherapy treatment.
- thermotherapy treatments according to the invention for one of early-stage breast cancer, locally advanced breast cancer, benign breast lesions and breast cancer prevention it is preferred that skin temperatures remain below approximately 40 to 42° C during treatment.
- tumor temperatures may be generated in the range of approximately 43 to 50 °C or higher.
- FIG. 5 shows a preferred system for heating carcinomas in intact breast, using an adaptive microwave phased array hyperthermia system with E-field and temperature feedback.
- an adaptive microwave phased array hyperthermia system with E-field and temperature feedback.
- the black circle indicated as focus 190, represents a tumor or healthy tissue that is to be treated.
- an E-field feedback probe 175 is used to focus the microwave radiation
- temperature feedback sensors 410 attached to the breast surface skin are used to adjust the microwave power level to heat the tumor to a desired temperature.
- a two-channel adaptive phased array is used to heat deep tissues within a compressed breast similar to the geometry used in x-ray mammography.
- the E-field probe is used with an adaptive phased array fast-acceleration gradient search algorithm, as disclosed in U.S. Pat. No. 5,810,888 to Fenn, to target the microwave radiation at the tumor site.
- air-cooled waveguide applicator apertures preferably are used to provide a heating pattern that can heat large volumes of breast tissue containing ductal and glandular carcinomas.
- the air for cooling the waveguide apertures can be refrigerated, air-conditioned or room temperature.
- the high-water content ductal and glandular carcinoma tissues are expected to heat more rapidly than normal breast tissue.
- the treated region will be concentrated on the high-water content (cancerous and pre-cancerous) carcinoma tissue and benign lesions such as fibroadenomas and cysts, while sparing the normal (healthy) breast tissue.
- the body or breast is compressed between two compression plates 200, which are made from a dielectric such as plexiglass that is transparent to microwaves.
- Breast compression has a number of potential advantages for intact breast hyperthermia treatments. Utilization of breast compression results in less penetration depth required to achieve deep microwave heating and reduces blood flow which also improves the ability to heat tissue. Compressing the breast to a flat surface improves the interface and electric-field coupling between the microwave applicator and the breast tissue, and allows a single pair of applicators to treat a wide range of breast sizes. Cooling of the breast compression plates with air during hyperthermia treatments helps avoid the potential for skin-surface hot spots.
- Compressing the breast with the patient in a prone position such as that used in 20 to 40 minute stereotactic needle breast biopsy procedures (Bassett et al., A Cancer Journal for Clinicians, Vol. 47, pp. 171-190, 1997), maximizes the amount of breast tissue within the compression device. Mild compression immobilizes the breast tissue such that any potential patient motion complications are eliminated.
- the compression plates 200 which can include small apertures, are compatible with x-ray and ultrasound imaging techniques to accurately locate the central glandular/ductal region and assist in the placement ofthe invasive E-field probe sensor.
- the amount of compression can be varied from about 4 to 8 cm to accommodate patient tolerance during a 20 to 40 minute or longer hyperthermia treatment.
- E-field probe 175 Prior to hyperthermia treatment, the breast is compressed between compression plates 200 and a single invasive E-field feedback sensor 175 is inserted within the central glandular/ductal/tumor tissue site (focus 190) in the breast, parallel to the polarization of the microwave applicators 100.
- E-field probe 175 is used in monitoring the focal E-field amplitude as the phase shifters are adjusted for maximum feedback signal using an adaptive phased array gradient search algorithm.
- Noninvasive temperature probes 410 are taped or otherwise secured to the skin surface of the breast to monitor the skin temperature. The temperature probes are typically oriented at right angles to the E-field polarization so as not to be heated by the microwave energy.
- the dual-applicator adaptive phased array of the invention together with the E-field feedback probe allows the phase shifters to be adjusted so that a concentrated E-field can be generated permitting focused heating in tissue at depth.
- Figures 6 and 14 to 17 show an embodiment of safety methods applied to externally focused adaptive microwave phased array thermotherapy for treatment of breast tumors (malignant and benign).
- the patient lies prone with the breast pendulant through a hole in the treatment table 210 and the treated breast 220 is compressed with flat plastic compression plates 200, which immobilize the breast tissue, reduce blood flow, and reduce the penetration depth required for the microwave radiation.
- the treatment table 210 may be similar to a stereotactic imaging breast needle biopsy table such as manufactured by Fischer Imaging (Denver, Colorado) in which the table is metallic and covered by a soft pad for patient comfort.
- the metallic bed serves as a rigid structural support.
- the metallic table 210 also serves as a shield to microwave radiation so that the entire body, in particular the patient's head and eyes, are fully protected from any stray microwave radiation from the microwave applicators 100.
- the metallic table 210 can be fabricated from aluminum or steel or from plastic with either a metal foil or metal mesh coating.
- the table pad 212 can be a foam material and may contain microwave-absorbing material for additional shielding from stray microwave radiation from the applicators.
- the breast compression plates are made of a microwave transparent plastic material, and may contain one or more apertures of rectangular or circular shape to allow imaging of breast tissues and placement of a minimally invasive E-field feedback probe 175 at the desired focal depth. Insertion of E-field feedback probe 175 may be achieved under the guidance of an ultrasound transducer.
- air flow 180 is provided by one or more cool-air fans (not shown).
- two or more temperature feedback probe sensors 410 are attached to the breast skin surface and produce the temperature feedback signals 400.
- Two microwave air-cooled waveguide applicators 100 are positioned on opposite sides ofthe compression plates 200.
- a 915 MHz microwave oscillator 105 is divided at node 107 and feeds phase shifters 120.
- the phase control signal 125 controls the phase of the microwave signal over the range of 0 to 360 electrical degrees.
- the microwave signal from phase shifter 120 feeds into the microwave power amplifier 130 which is controlled by a computer-generated control signal 135, which sets the initial microwave power level.
- Coherent 915 MHz microwave power is delivered to the two waveguide applicators 100 while phase shifters 120 in each channel are adjusted to maximize and focus the microwave energy at the E-field probe sensor 175 so that microwave power is maximized at the focus position 190.
- the treatment then begins. [059] During the hyperthermia treatment, the microwave power level delivered to each of the applicators 100 is measured as a feedback signal 500, and the power control is adjusted either manually or automatically to control the skin temperatures and equivalent thermal dose measured by the skin sensors 410 to avoid high temperatures that could cause skin burns or blisters. The amount of breast compression is adjusted by the compression plates 200 as necessary during treatment to provide patient comfort.
- the phase shifters 120 are readjusted/refocused so that the E-field probe sensor 175 receives maximum power.
- the total microwave energy, since the start of the treatment, delivered to the microwave applicators is computed within the computer 250 and displayed on the computer monitor 260 during the treatment.
- the treatment is completed when a desired amount of total microwave energy is delivered to the microwave applicators 100.
- the total microwave energy calculated from the E-field feedback signal 450 received by the E-field probe 175 is used to control the length of the treatment.
- the breast tissue is imaged with mammography means including x-ray and magnetic resonance imaging before and after the microwave total energy dose is administered, as well as pathological results from needle biopsy ofthe breast tissues.
- the single invasive E-field probe 175 is replaced with two noninvasive E-field probes 185 positioned on the opposing skin surfaces.
- the total power measured by the two noninvasive E-field probes is minimized (as in U.S. Pat. No. 5,810,888) by adjusting the microwave phase shifters 120, creating a focused E-field probe in the central portion of the breast.
- there is no risk of infection due to an inserted probe there is no risk of scarring ofthe breast skin by the procedure of nicking the skin and inserting the probe, and any risk of spreading cancer cells by the probe passing through the tumor bed is avoided.
- both the temperature and E-field probes can be placed on the breast skin with this method embodiment, this method would work well when there is no defined single area.
- each channel (on either side of node 107) of the phased array contains an electronically-variable microwave power amplifier 130 (0 to 100 W), an electronically- variable phase shifter 120 (0 to 360 degrees), and air-cooled linearly-polarized rectangular waveguide applicators 100.
- Applicators 100 may be Model Number TEM-2 manufactured by Celsion Corporation, Columbia, MD.
- the rectangular aperture dimensions of a preferred pair of TEM-2 metallic waveguide applicators are 6.5 cm by 13.0 cm.
- microwave energy at approximately 915 MHz the frequency ofthe microwave energy may be between 100 MHz and 10 GHz.
- the frequency ofthe microwave energy could be selected from the range of 902 MHz and 928 MHz.
- the initial microwave power delivered to each waveguide application is between 20 and 60 Watts. Over the entire treatment ofthe tissue, the microwave power delivered to each waveguide application may be adjusted over the range of 0-150 Watts to deliver the desired microwave energy dose and to avoid overheating the skin.
- Dielectric loading of the side walls of the rectangular waveguide region of applicators 100 is used to obtain good impedance matching conditions for the TEM applicator microwave radiation (Cheung et al., "Dual-beam TEM applicator for direct-contact heating of dielectrically encapsulated malignant mouse tumor", Radio Science, Vol.
- the effective cross-sectional size for the air-cooling is approximately 6.5 cm by 9.0 cm for the TEM-2 applicator.
- the high-water content ductal and glandular carcinomas and benign lesions are expected to heat more rapidly than normal breast tissue.
- the 50%) SAR region will be concentrated on the high-water content (cancerous, pre- cancerous, and benign lesions including fibroadenomas and cysts) tissue while sparing the normal tissue.
- a 0.9-mm outside-diameter (OD) invasive E-field coaxial monopole probe (semi-rigid RG-034), with the center conductor extended 1 cm, can be used to measure the amplitude ofthe electric field directed to the tissue and provide the feedback signal used to determine the necessary relative phase for the electronic phase shifters prior to treatment.
- Coaxially-fed monopole probes of this type have been used to make accurate measurements of linearly polarized electric fields in compressed breast phantoms (Fenn et al., International Symposium on Electromagnetic Compatibility 17-19 May 1994 pp. 566-569) Journal of Hyperthermia, Vol. 10, No. 2, March- April, pp.
- This linearly-polarized E-field probe is inserted within a 1.5 mm OD teflon catheter.
- Thermocouple probes (Physitemp Instruments, Inc., Type T copper-constantan, enclosed within a 0.6 mm OD teflon catheter) were used to measure the local temperature in the tumor during treatment. These temperature probes have a response time of 100 ms with an accuracy of 0.1 ° C.
- the E-field probe was used with the adaptive phased array fast-acceleration gradient search algorithm, as disclosed in U.S. Pat. No. 5,810,888 to Fenn, to target the microwave radiation at the tumor site.
- the temperature sensed by the invasive temperature probe in the tumor was used as a real-time feedback signal during the treatment.
- This feedback signal was used to control the microwave output power level ofthe variable power amplifiers, which set and maintained the focal temperature at the tumor site in the range of 43 to 46° C.
- the power and phase delivered to the two channels of the phased array were adjusted adaptively using digital-to-analog converters under computer control.
- the breast compression plates were made of an acrylic material (plexiglass) which is a low-loss dielectric material and nearly transparent to microwave fields.
- the compression plates contained square cut-outs (apertures), approximately 5.5 cm on a side, which accommodate small ultrasound transducers (nominally 4 cm in length) to assist in placement of the minimally invasive probes (E-field and temperature).
- the cut-outs also allow improved air flow to cool the skin.
- the Total Microwave Energy Dose can be used to estimate the required heating time. That is, Applicants realized that a non-invasive equivalent temperature sensing means could replace the invasive temperature probes, and that the Total Microwave Energy Dose reliably could be used to control the duration of treatment.
- Table 1 the average thermal dose is 45.1 minutes and the average Total Microwave Energy is 169.5 kJ.
- the maximum energy value (192.0 kJ) varies by only 13% from the average and the minimum energy value (138.0 kJ) varies by only 14% from the average.
- the breast compression used in these tests reduces blood flow which likely eliminates the effects of blood flow on the required microwave energy for treatment, and may help explain the small variation in energy required in these tests.
- post treatment imaging of these four tests typically showed significant damage to the tumor, but little or no damage to the skin, breast fat, and normal glandular, ductal, and connective tissues.
- the total microwave energy delivered to the waveguide applicators to determine completion of the treatment is between 25 kilojoules and 250 kilojoules.
- the total amount of microwave energy dose that would destroy any cancerous or precancerous tissue would be approximately 175 kilojoules. But, under certain conditions, the required microwave energy dose may be as low as 25 kilojoules. In another embodiment according to the invention, higher microwave energy doses up to 400 kilojoules may be employed to completely destroy cancerous tumor cells.
- Table 2 below lists the breast tissue compression thickness for the four tests. It should be noted that the smallest compression thickness (4.5 cm) corresponds to the smallest energy dose (138 kJ) delivered, with both occurring in Test 4. As applicants recognized and will be proven theoretically below, smaller compression thickness may require less microwave energy dose (compared to larger compression thickness) for effective treatments in preventing or destroying cancerous, pre-cancerous or benign lesions.
- Doppler ultrasound can be used to measure blood flow in tumors and surrounding breast tissue, before and during treatment to plan and adjust the microwave energy dose. For example, less energy dose is required when the tumor blood flow rate is reduced which can occur when the breast is compressed and/or the tumor is heated to therapeutic temperatures.
- the water content and dielectric parameters of breast tumor tissue from needle biopsies could be measured and used to determine, prior to the treatment, the required microwave energy dose. For example, higher water content and higher electrical conductivity in the tumor would reduce the amount of required microwave energy dose.
- the size ofthe tumor impacts the required microwave energy dose. Larger tumors are more difficult to heat than smaller tumors and require a larger microwave energy dose.
- An initial treatment planning session involving a low- dose delivery of microwave energy to assess the heatability ofthe tumor, followed by a complete treatment at the full required microwave energy dose may be performed.
- Microwave energy from hyperthermia applicators in the near field of a body, radiates as a spherical wave with the electric-field amplitude varying, in part, as the inverse of the radial distance r from the applicator. Additionally, the amplitude decays as an exponential function ofthe product ofthe attenuation constant of the body tissue and the distance d traversed (or depth) within the body.
- the electric-field phase varies linearly with distance according to the product ofthe phase propagation constant ⁇ and distance d.
- dual-opposing applicators are analyzed here under the assumption that the applicator radiation is approximated by a plane wave.
- Plane-wave electromagnetic energy at the microwave frequency of 915 MHz, attenuates at a rate of about 3 dB per cm in high-water content tissue, such as ductal or glandular breast tumor, and about 1 dB per cm in normal breast tissue.
- a single radiating applicator has a significant fraction of its microwave energy absorbed by intervening superficial body tissue compared to the energy that irradiates deep tissue, likely creating a hot spot in superficial tissue. Since skin surface cooling with either air or water protects tissue only to a maximum depth of about 0.25 to 0.5 cm, in order to avoid hot spots, it is necessary to introduce a second phase-coherent applicator, having the same microwave radiation amplitude as the first applicator.
- the second phase-coherent applicator can theoretically increase the power (and hence the energy) delivered to deep tissue by a factor of four compared to a single applicator (Field and Hand, p. 290, 1990).
- phase characteristics ofthe electromagnetic radiation from two or more applicators can have a pronounced affect on the distribution of power delivered to different tissues.
- the relative specific absorption rate (SAR) in homogeneous tissue is approximated by the square ofthe electric-field amplitude
- the SAR is proportional to the rise in temperature over a given time interval.
- the wavelength in homogeneous normal breast tissue (with approximate dielectric constant 12.5 and electrical conductivity 0.21 S/m (values averaged from Chaudhary et al., 1984, Joines et al., 1994) is approximately 9.0 cm at 915 MHz, and the microwave loss is (1 dB/cm).
- the attenuation constant a is 0.11 radians/cm and the propagation constant ⁇ is 0.69 radians/cm.
- the adaptive phased array system uses two microwave channels, fed by a common oscillator 105, containing two electronically adjustable phase shifters 120 to focus the microwave energy at an E-field feedback probe 175.
- This inventive adaptive phased array system has significant advantage over a non-adaptive phased array.
- a non-adaptive phased array with two channels could, in theory, produce a null, a maximum, or an intermediate value of E-field depending on whether the two waves are 180 degrees out-of-phase, completely in- phase, or partly out-of-phase, respectively. That is, the microwave phase delivered to the microwave applicators, according to the invention, can be adjusted between -180 degrees and 180 degrees before and during the treatment to create a focused field in the breast tissue.
- the adaptive phased array according to the invention automatically focuses the E-field in the presence of all scattering structures in the tissue, this type of array should provide more reliable deep focused heating compared to manually adjusted or pre-treatment planning controlled phased arrays as described in U.S. Patent No. 4,589,423 to Turner. Furthermore, the adaptive phased array system according to the preferred embodiment of the invention does not use an invasive metallic temperature probe which could scatter or alter the E-field at the tumor site. Calculation of Microwave Energy
- 2 4P exp(- ⁇ D) . (2)
- Equation (2) was used to compute the focused 915 MHz energy per unit time at the central depth of normal breast tissue varying in thickness from 4 cm to 8 cm with the attenuation constant equal to 0.11 radians/cm, as shown in Table 4 and Figure 7.
- the applicators were coherently combined to focus the radiated beam at the central position in 6 cm thick homogeneous normal (mixture of fat and glandular) breast tissue.
- the applicators are assumed to radiate through thin sheets of plexiglass that simulate the plates used for breast compression in the adaptive phased array breast hyperthermia system.
- Each metallic waveguide is loaded on the side walls with high dielectric constant material, which is used to match and shape the radiation inside the waveguide aperture.
- the waveguide applicators are linearly polarized with the alignment ofthe E-field in the y direction as in Figure 8.
- a flat sheet of 3 mm thick plexiglass is adjacent to each applicator and parallel to the waveguide aperture. Between the two opposing TEM-2 applicators is a 6 cm thick homogeneous normal breast tissue phantom. The remaining volume is filled with cubic cells that model air.
- the SAR distributions were calculated by squaring the electric field amplitude and multiplying by the electrical conductivity ofthe tissue. SAR is often described in levels (50% is usually designated as the effective heating zone) relative to the maximum SAR value of 100%. The SAR is proportional to the initial rise in temperature per unit time ignoring blood flow and thermal conduction effects.
- the SAR patterns were computed in the three principal planes (xy, xz, yz) as shown in Figures 9 to 13 for homogeneous normal breast tissue.
- the pattern generally is bell shaped and centered between the TEM-2 applicators.
- the pattern exhibits a small elliptically shaped 75% SAR region surrounded by a three-lobe shaped elliptical 50% SAR region.
- the pattern exhibits a small circularly shaped 75% SAR region surrounded by a three-lobe shaped elliptical 50%> SAR region approximately the size ofthe waveguide aperture.
- Figure 14 shows the externally focused adaptive phased array thermotherapy system od Figure 5 with two of the safety methods applied to the waveguide applicators 100.
- a thin metallic shielding strip 605 of width 1 to 2 cm covers the top section ofthe rectangular waveguide aperture 600 to block stray radiation from reaching the base ofthe breast near the chest wall region.
- a thin microwave absorbing pad 610 (for example, 0.125-inch thick Cuming Microwave Corporation MT-30 sheet absorber, attenuation 40 dB/inch) covers the entire top surface ofthe waveguide applicator 100 (for example, Celsion Corporation TEM2 waveguide applicator).
- the microwave absorbing pad 610 can attenuate or suppress any microwave surface currents that could reradiate microwave energy toward the base ofthe breast and chest wall region.
- the microwave-absorbing pad 610 is glued or otherwise attached to the top surface ofthe waveguide applicator.
- Figure 15 shows a side view ofthe externally focused adaptive phased array thermotherapy applicators 100 with breast compression plates (paddles) 200 on either side of a simple T-shaped breast phantom 700 that is used to simulate the breast for microwave heating experiments.
- the applicators 100 have pads 610 and microwave shielding strip 605 with additional insulating pads 620 placed between compression plate 200 and the phantom T 700 representing the chest wall or muscle supporting the breast tissue.
- a T-shaped phantom enclosure is fabricated preferably from plexiglass or other plastic material and is part of compression plates 200.
- the upper "T" section of compression plates 200 extends between pad 610 and pad 620 for a distance, as shown in Figure 15.
- the upper section ofthe T- shaped breast phantom 700 contains muscle equivalent phantom tissue (M. Gauthrie, editor: Methods of External Hypeithermic Heating, Springer Verlag, p. 11 (Chou formulation), 1990) and the lower section contains fatty dough breast equivalent phantom tissue (J.J. W. Lündijk and P.
- Applicators 100 are designed so that a gap region 635 is provided between the applicator and the breast tissue. Gap region 635 allows airflow from external air tubes or fans that are pointed into the gap to cool the region in proximity to the base of each side ofthe breast and chest wall region.
- plastic air tubes with flared or conical shaped nozzles such as those manufactured by Lockwood Products, Inc., Lake Oswego, OR may be used to guide airflow into gap region 635 to cool the breast region.
- a fiber optic temperature sensor probe 415 and an E-field microwave- focusing probe 175 are parallel to one another and co-located within a single catheter.
- the tip ofthe fiber optic temperature sensor is positioned within the tumor site or focus position 190 and the E-field focusing probe 175 is located at the same depth ofthe tumor as measured between the compression plates.
- the fiber optic temperature sensor in the tumor can be ofthe fluroroptic type is non- metallic and does not interfere with the microwave energy (M. Gauthrie, editor: Methods of External Hyperthermic Heating, Springer Verlag, p. 119, 1990).
- the metallic E-field focusing probe 175 consists of very thin metallic coaxial cable 0.020 inches diameter (UT-20).
- the tip section ofthe E-field focusing probe 175 consists ofthe center pin ofthe coaxial cable extending approximately 1 cm beyond the outer jacket of the coaxial cable.
- the tip of the E-field focusing probe is positioned approximately 0.5 cm from the tip ofthe fiber optic temperature sensor.
- Figure 16 shows a more realistically shaped breast phantom 710 in which the breast is curved.
- the curved breast portion can be fabricated using a plastic bag (polyethylene) filled with a compressible fat phantom material conforming to the shape of a breast. Compressible ultrasound breast imaging phantoms can also be used for microwave experiments.
- the positions labeled 7 and 8 are on the skin surface close to the base ofthe breast near the chest wall region.
- a portion (lower portion below the skin entry point) ofthe metallic coaxial E-field focusing probe 175 is not shielded by the breast tissue and is directly exposed to the microwave energy radiated by the two waveguide applicators 100.
- the microwave energy can possibly overheat the exposed metallic coaxial cable resulting in a skin burn where the E-field focusing probe enters the skin. In such a case, it is desirable to remove the E-field focusing probe 175 after the microwave focusing procedure is completed prior to heating the breast.
- the preferred E-field focusing probe 175 is a coaxial cable with the center pin extended to form a monopole antenna.
- the focusing probe can also be fabricated using a monopole or dipole antenna connected to parallel transmission lines of either metallic or carbon material.
- the focusing probe can be a monopole or dipole antenna with a microwave to optical converter connected to a fiber optic cable to avoid metallic heating effects at the skin entry point.
- the optical modulator may be a Mach Zehnder modulator, for example.
- Figure 17 shows a detailed three-dimensional view of the improved safety method with compression plate 200 and pad 620.
- the compression plate edge 210 is a potential source for damage to the skin as a right angle is formed by the vertical and horizontal surfaces of the plate and the edge is adjacent the chest wall and breast tissue. Accordingly, microwave-absorbing pad 620 is disposed between edge 210 and the chest wall.
- the microwave-absorbing pad 620 serves two purposes. First, the pad contains a soft foam material and cushions the breast skin from abrasion or pressure as the breast is compressed against the compression plate edge 210. Second, the pad contains microwave-absorbing material to attenuate any stray microwave radiation from the applicators 100 that might overheat nearby tissue.
- the compression plate 200 or paddle may contain one or more rectangular openings 205 to allow an ultrasound transducer to touch the skin for imaging the breast tissue while the E-field focusing probe and temperature probe are inserted in the breast tumor region.
- Figure 18 shows a side view ofthe waveguide applicators 100 and compression plates 200 with metallic shielding strips 615 glued or otherwise attached to the surface ofthe compression plates 200 facing away from the breast skin. Shielding Experiment Results
- Figure 15 shows the geometry of externally focused adaptive phased array microwave thermotherapy for breast tumor treatment.
- two Celsion Corporation TEM-2 microwave applicators radiating at 915 MHz were used to induce thermotherapy.
- the patient tissue is represented by a phantom consisting of a T-shaped plexiglass box containing simulated breast tissue in the lower portion and simulated muscle tissue in the upper portion.
- a simulated breast tumor consisting of muscle phantom tissue (approximately 1.5 cm diameter) was located at position 1. Seven temperature probes (designated #1 to #7) were used in these experiments. Probe 1 was a fiberoptic temperature probe and the remaining probes were thermocouple probes that rest outside the simulated skin ofthe breast tissue.
- Probe 1 was positioned at the desired focus site 190 where the simulated tumor position is located. Probes 2 and 3 were located at the top comer of the compression paddles outside of the primary microwave field. Probes 4 and 5 were located in the center ofthe microwave field where the maximum field strength exists. Probes 6 and 7 were located above probes 4 and 5 where a lower field strength would be expected.
- An E-field focusing probe 175 was also placed at the same depth as Probe position 1 to focus the microwave energy. The E-field focusing probe 175 and fiber optic temperature probe 1 were inserted within a common catheter (Teflon, 1.65mm outer diameter).
- Table 6 Measured temperature slopes with absorber on top ofthe breast compression plate and on top of waveguide applicator and shielding covering the top section ofthe applicators.
- any type of focused energy including electromagnetic, ultrasound, radio frequency, laser or other focused energy source that is known to those skilled in the art. That is, any energy or combination of different energies that can be focused to heat and ablate an area of tissue may be employed in the method according to Applicants' invention. While the focused energy may be the primary heating source, it may be combined with an injection of substance that increases or enhances heating at the target area (tumor). The substance may be saline water or water mixed with a metal or other electrical conducting substance, such as a metallic surgical breast clip so that the substance enhances the amount of heat delivered to the target area.
- the hyperthermia system described herein is with respect to the treatment of breast carcinomas and benign breast lesions, the invention is applicable to the treatment of other types of cancers such as prostate, liver, lung, and ovarian as well as benign disease such as benign prostatic hyperplasia (BPH).
- BPH benign prostatic hyperplasia
- the safety methods disclosed here can be applied to microwave or radiofrequency thermotherapy treatments of other appendages and portions of the human body such as legs and arms and the torso.
- larger or smaller numbers of array antenna applicators, or a single antenna applicator may be used with similar results.
- the methods disclosed here can be used with non-coherent multiple-applicator treatment systems - in a non-coherent system, a field focusing probe would not be necessary.
- the compression step can be omitted. If the compression step is not used, then the absorbing pads and other metallic shielding features may not be employed.
- Some of the methods and techniques described herein are also applicable to ultrasound hyperthermia system particularly the use of energy dose for feedback control.
- the method can be used to enhance radiation therapy or for targeted drug delivery using thermosensitive liposomes and/or targeted gene delivery.
- the invention is also applicable to non-medical hyperthermia systems, such as those used for heating of industrial or food materials.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05000565A MXPA05000565A (en) | 2002-07-12 | 2003-07-11 | Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs. |
EP03764473A EP1523370A1 (en) | 2002-07-12 | 2003-07-11 | Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
CN038166089A CN1668359B (en) | 2002-07-12 | 2003-07-11 | Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
CA2491924A CA2491924C (en) | 2002-07-12 | 2003-07-11 | Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
AU2003253877A AU2003253877A1 (en) | 2002-07-12 | 2003-07-11 | Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
JP2004521650A JP2005532868A (en) | 2002-07-12 | 2003-07-11 | Hyperthermia for the treatment and prevention of breast cancer and cancers of other organs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/193,110 | 2002-07-12 | ||
US10/193,110 US6690976B2 (en) | 2000-04-13 | 2002-07-12 | Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004007020A2 true WO2004007020A2 (en) | 2004-01-22 |
Family
ID=30114467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/021655 WO2004007020A2 (en) | 2002-07-12 | 2003-07-11 | Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
Country Status (8)
Country | Link |
---|---|
US (1) | US6690976B2 (en) |
EP (1) | EP1523370A1 (en) |
JP (1) | JP2005532868A (en) |
CN (1) | CN1668359B (en) |
AU (1) | AU2003253877A1 (en) |
CA (1) | CA2491924C (en) |
MX (1) | MXPA05000565A (en) |
WO (1) | WO2004007020A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1539298A1 (en) * | 2002-07-16 | 2005-06-15 | Celsion Corporation | Method for improved safety in externally focused microwave thermotherapy for treating breast cancer |
EP3628251A1 (en) * | 2018-09-28 | 2020-04-01 | Koninklijke Philips N.V. | Ablation therapy planning system |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7229436B2 (en) * | 1996-01-05 | 2007-06-12 | Thermage, Inc. | Method and kit for treatment of tissue |
US7141049B2 (en) * | 1999-03-09 | 2006-11-28 | Thermage, Inc. | Handpiece for treatment of tissue |
GB0111986D0 (en) * | 2001-05-16 | 2001-07-04 | Optomed As | Cryosurgical apparatus and methods |
US20040206738A1 (en) * | 2001-12-28 | 2004-10-21 | Ge Medical Systems Global Technology Company, Llc | Mammography patient contact temperature controller |
US8481082B2 (en) * | 2002-02-14 | 2013-07-09 | Gholam A. Peyman | Method and composition for hyperthermally treating cells |
US6807446B2 (en) * | 2002-09-03 | 2004-10-19 | Celsion Corporation | Monopole phased array thermotherapy applicator for deep tumor therapy |
ATE398974T1 (en) | 2002-11-27 | 2008-07-15 | Medical Device Innovations Ltd | COAXIAL TISSUE ABLATION SAMPLE AND METHOD FOR PRODUCING A BALANCER THEREOF |
US7722601B2 (en) | 2003-05-01 | 2010-05-25 | Covidien Ag | Method and system for programming and controlling an electrosurgical generator system |
SE527164C2 (en) * | 2003-05-14 | 2006-01-10 | Spectracure Ab | Interactive therapy/diagnosis system for tumor, has operation mode selector to optically direct non-ionizing electromagnetic therapeutic and/or diagnostic radiation to tumor site, through radiation conductor |
US20070122529A1 (en) * | 2003-08-21 | 2007-05-31 | Advanced Nutri-Tech Systems Inc. | Fruit sponge |
EP1537871A1 (en) * | 2003-12-04 | 2005-06-08 | Aventis Pharma S.A. | Enoxaparin for the treatment of cancer |
ATE489034T1 (en) | 2004-05-26 | 2010-12-15 | Medical Device Innovations Ltd | TISSUE DETECTION AND ABLATION DEVICE |
US7670282B2 (en) * | 2004-06-14 | 2010-03-02 | Pneumrx, Inc. | Lung access device |
WO2006009688A2 (en) * | 2004-06-16 | 2006-01-26 | Pneumrx, Inc. | Intra-bronchial lung volume reduction system |
US7766891B2 (en) * | 2004-07-08 | 2010-08-03 | Pneumrx, Inc. | Lung device with sealing features |
EP1781182B1 (en) * | 2004-07-08 | 2019-11-13 | PneumRx, Inc. | Pleural effusion treatment device |
NZ582466A (en) | 2004-07-30 | 2011-09-30 | Adeza Biomedical Corp | Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin |
US20060079774A1 (en) * | 2004-10-08 | 2006-04-13 | Wendell Anderson | Microwave biopsy probe |
JP4874259B2 (en) | 2004-11-23 | 2012-02-15 | ヌームアールエックス・インコーポレーテッド | Steerable device for accessing the target site |
EP1835929B8 (en) | 2005-01-06 | 2016-07-27 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
WO2006077567A1 (en) * | 2005-01-18 | 2006-07-27 | Msq Ltd. | Improved system and method for heating biological tissue via rf energy |
US20060199159A1 (en) * | 2005-03-01 | 2006-09-07 | Neuronetics, Inc. | Head phantom for simulating the patient response to magnetic stimulation |
US8765116B2 (en) * | 2005-03-24 | 2014-07-01 | Medifocus, Inc. | Apparatus and method for pre-conditioning/fixation and treatment of disease with heat activation/release with thermoactivated drugs and gene products |
US7942873B2 (en) * | 2005-03-25 | 2011-05-17 | Angiodynamics, Inc. | Cavity ablation apparatus and method |
DE102005022608B3 (en) * | 2005-05-11 | 2007-01-11 | Karl Storz Gmbh & Co. Kg | Light system for photodynamic diagnosis and / or therapy |
US20060264832A1 (en) * | 2005-05-20 | 2006-11-23 | Medtronic, Inc. | User interface for a portable therapy delivery device |
US8550743B2 (en) | 2005-09-30 | 2013-10-08 | Medtronic, Inc. | Sliding lock device |
US7565207B2 (en) * | 2005-11-22 | 2009-07-21 | Bsd Medical Corporation | Apparatus for creating hyperthermia in tissue |
US8170643B2 (en) * | 2005-11-22 | 2012-05-01 | Bsd Medical Corporation | System and method for irradiating a target with electromagnetic radiation to produce a heated region |
AU2006325835A1 (en) * | 2005-12-14 | 2007-06-21 | Global Resource Corporation | Device producing and use of microwave energy for thermotherapy |
EP1969088A2 (en) * | 2005-12-14 | 2008-09-17 | Mobilestream Oil Inc. | Microwave-based recovery of hydrocarbons and fossil fuels |
GB2435039B (en) * | 2006-02-02 | 2010-09-08 | John Frederick Novak | Method and apparatus for microwave reduction of organic compounds |
US8888800B2 (en) | 2006-03-13 | 2014-11-18 | Pneumrx, Inc. | Lung volume reduction devices, methods, and systems |
US8157837B2 (en) * | 2006-03-13 | 2012-04-17 | Pneumrx, Inc. | Minimally invasive lung volume reduction device and method |
US9402633B2 (en) | 2006-03-13 | 2016-08-02 | Pneumrx, Inc. | Torque alleviating intra-airway lung volume reduction compressive implant structures |
CN100518684C (en) * | 2006-06-30 | 2009-07-29 | 南京福中信息产业集团有限公司 | Cold circulation microwave tumor therapeutic apparatus |
US9517240B2 (en) | 2006-09-26 | 2016-12-13 | The Regents Of The University Of California | Methods and compositions for cancer prevention and treatment |
WO2008039482A2 (en) * | 2006-09-26 | 2008-04-03 | The Regents Of The University Of California | Methods and compositions for cancer prevention and treatment |
US8048069B2 (en) * | 2006-09-29 | 2011-11-01 | Medtronic, Inc. | User interface for ablation therapy |
US8945114B2 (en) * | 2007-04-26 | 2015-02-03 | Medtronic, Inc. | Fluid sensor for ablation therapy |
US8323694B2 (en) * | 2007-05-09 | 2012-12-04 | Nanoprobes, Inc. | Gold nanoparticles for selective IR heating |
US8423152B2 (en) * | 2007-05-14 | 2013-04-16 | Bsd Medical Corporation | Apparatus and method for selectively heating a deposit in fatty tissue in a body |
US9387036B2 (en) * | 2007-05-14 | 2016-07-12 | Pyrexar Medical Inc. | Apparatus and method for selectively heating a deposit in fatty tissue in a body |
US20090306646A1 (en) * | 2007-05-14 | 2009-12-10 | Bsd Medical Corporation | Apparatus and method for injection enhancement of selective heating of a deposit in tissues in a body |
US9861424B2 (en) | 2007-07-11 | 2018-01-09 | Covidien Lp | Measurement and control systems and methods for electrosurgical procedures |
US8152800B2 (en) | 2007-07-30 | 2012-04-10 | Vivant Medical, Inc. | Electrosurgical systems and printed circuit boards for use therewith |
US7645142B2 (en) | 2007-09-05 | 2010-01-12 | Vivant Medical, Inc. | Electrical receptacle assembly |
US8747398B2 (en) | 2007-09-13 | 2014-06-10 | Covidien Lp | Frequency tuning in a microwave electrosurgical system |
US20110230568A1 (en) * | 2008-07-24 | 2011-09-22 | Childrens Medical Center Corporation | Heating of polymers and other materials using radiation for drug delivery and other applications |
WO2010011319A2 (en) * | 2008-07-24 | 2010-01-28 | Children's Medical Center Corporation | Magnetic heating for drug delivery and other applications |
US20110212027A1 (en) * | 2008-07-24 | 2011-09-01 | Children's Medical Center Corporation | Radiative heating for drug delivery and other applications |
US9173669B2 (en) | 2008-09-12 | 2015-11-03 | Pneumrx, Inc. | Enhanced efficacy lung volume reduction devices, methods, and systems |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US8968210B2 (en) * | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US20100087808A1 (en) * | 2008-10-03 | 2010-04-08 | Vivant Medical, Inc. | Combined Frequency Microwave Ablation System, Devices and Methods of Use |
US20100100090A1 (en) * | 2008-10-17 | 2010-04-22 | Medicold Limited | Thermotherapy application and control system |
CN104622599B (en) | 2009-05-18 | 2017-04-12 | 纽姆克斯股份有限公司 | Cross-sectional modification during deployment of an elongate lung volume reduction device |
US8834460B2 (en) | 2009-05-29 | 2014-09-16 | Covidien Lp | Microwave ablation safety pad, microwave safety pad system and method of use |
US10828100B2 (en) * | 2009-08-25 | 2020-11-10 | Covidien Lp | Microwave ablation with tissue temperature monitoring |
US20110123452A1 (en) * | 2009-11-25 | 2011-05-26 | Nanoprobes, Inc. | Metal oligomers and polymers and their use in biology and medicine |
US8882759B2 (en) * | 2009-12-18 | 2014-11-11 | Covidien Lp | Microwave ablation system with dielectric temperature probe |
US8313486B2 (en) | 2010-01-29 | 2012-11-20 | Vivant Medical, Inc. | System and method for performing an electrosurgical procedure using an ablation device with an integrated imaging device |
US8568404B2 (en) | 2010-02-19 | 2013-10-29 | Covidien Lp | Bipolar electrode probe for ablation monitoring |
DE102010018001A1 (en) * | 2010-04-23 | 2011-10-27 | Siemens Aktiengesellschaft | SAR estimation in nuclear magnetic resonance studies using microwave thermometry |
US9204922B2 (en) | 2010-12-01 | 2015-12-08 | Enable Urology, Llc | Method and apparatus for remodeling/profiling a tissue lumen, particularly in the urethral lumen in the prostate gland |
US8951266B2 (en) | 2011-01-07 | 2015-02-10 | Restoration Robotics, Inc. | Methods and systems for modifying a parameter of an automated procedure |
US8317703B2 (en) | 2011-02-17 | 2012-11-27 | Vivant Medical, Inc. | Energy-delivery device including ultrasound transducer array and phased antenna array, and methods of adjusting an ablation field radiating into tissue using same |
CN102728002A (en) * | 2011-06-20 | 2012-10-17 | 广东中能加速器科技有限公司 | Movable horizontal intraoperative radiotherapy apparatus |
US10390838B1 (en) | 2014-08-20 | 2019-08-27 | Pneumrx, Inc. | Tuned strength chronic obstructive pulmonary disease treatment |
CN109414587A (en) * | 2016-06-17 | 2019-03-01 | 强普生技股份有限公司 | The method for treating tumour |
JP2019526304A (en) * | 2016-06-29 | 2019-09-19 | ニラマイ・ヘルス・アナリティックス・ピーブイティー・エルティーディ | Classification of hormone receptor status in malignant neoplastic tissue by chest thermography image |
US20180264285A1 (en) * | 2017-03-18 | 2018-09-20 | Rodney D. Smith | Breast Cup System and Method for Hyperthermic Anaerobic Cell Apoptosis |
US20210198753A1 (en) * | 2018-06-21 | 2021-07-01 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems and methods for determining a treatment course of action |
JP7017493B2 (en) * | 2018-09-27 | 2022-02-08 | 富士フイルム株式会社 | Mammography device and its operation method, as well as image processing device and its operation program and operation method |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3895639A (en) | 1971-09-07 | 1975-07-22 | Rodler Ing Hans | Apparatus for producing an interference signal at a selected location |
US4589423A (en) | 1980-04-02 | 1986-05-20 | Bsd Medical Corporation | Apparatus for creating hyperthermia in tissue |
US5251645A (en) | 1991-06-26 | 1993-10-12 | Massachusetts Institute Of Technology | Adaptive nulling hyperthermia array |
US5441532A (en) | 1991-06-26 | 1995-08-15 | Massachusetts Institute Of Technology | Adaptive focusing and nulling hyperthermia annular and monopole phased array applicators |
US5540737A (en) | 1991-06-26 | 1996-07-30 | Massachusetts Institute Of Technology | Minimally invasive monopole phased array hyperthermia applicators and method for treating breast carcinomas |
US5810888A (en) | 1997-06-26 | 1998-09-22 | Massachusetts Institute Of Technology | Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery |
US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4341227A (en) | 1979-01-11 | 1982-07-27 | Bsd Corporation | System for irradiating living tissue or simulations thereof |
US4798215A (en) | 1984-03-15 | 1989-01-17 | Bsd Medical Corporation | Hyperthermia apparatus |
US4397313A (en) * | 1981-08-03 | 1983-08-09 | Clini-Therm Corporation | Multiple microwave applicator system and method for microwave hyperthermia treatment |
US4397314A (en) | 1981-08-03 | 1983-08-09 | Clini-Therm Corporation | Method and apparatus for controlling and optimizing the heating pattern for a hyperthermia system |
US4556070A (en) | 1983-10-31 | 1985-12-03 | Varian Associates, Inc. | Hyperthermia applicator for treatment with microwave energy and ultrasonic wave energy |
DK312884A (en) | 1984-06-27 | 1985-12-28 | Joergen Bach Andersen | APPLICATOR |
JPS62149347U (en) * | 1986-03-13 | 1987-09-21 | ||
JPH0317888Y2 (en) * | 1986-10-16 | 1991-04-16 | ||
JPH04276263A (en) * | 1991-02-27 | 1992-10-01 | Lti Imd Usa Inc | Shielded electromagnetic type transducer |
IT1247029B (en) | 1991-06-19 | 1994-12-12 | S M A Segnalamento Marittimo E | MICROWAVE EQUIPMENT FOR CLINICAL HYPERTHERMIA IN ENDOGENIC THERMOTHERAPY |
DE69214672T2 (en) * | 1991-12-20 | 1997-04-03 | Technomed Medical Systems | SOUNDWAVE EMITTING, THERMAL EFFECTS AND CAVITATION EFFECTS DEVICE FOR ULTRASONIC THERAPY |
US6245347B1 (en) * | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
US6350276B1 (en) * | 1996-01-05 | 2002-02-26 | Thermage, Inc. | Tissue remodeling apparatus containing cooling fluid |
US6126619A (en) * | 1997-09-02 | 2000-10-03 | Transon Llc | Multiple transducer assembly and method for coupling ultrasound energy to a body |
US6391026B1 (en) * | 1998-09-18 | 2002-05-21 | Pro Duct Health, Inc. | Methods and systems for treating breast tissue |
US6163726A (en) | 1998-09-21 | 2000-12-19 | The General Hospital Corporation | Selective ablation of glandular tissue |
US6436061B1 (en) * | 1999-12-29 | 2002-08-20 | Peter D. Costantino | Ultrasound treatment of varicose veins |
US6470217B1 (en) * | 2000-04-13 | 2002-10-22 | Celsion Corporation | Method for heating ductal and glandular carcinomas and other breast lesions to perform thermal downsizing and a thermal lumpectomy |
EP1647305B1 (en) * | 2000-06-20 | 2010-12-29 | Boston Scientific Corporation | System for heating a body organ |
JP2002011021A (en) * | 2000-06-29 | 2002-01-15 | Olympus Optical Co Ltd | Thermotherapy device |
-
2002
- 2002-07-12 US US10/193,110 patent/US6690976B2/en not_active Expired - Lifetime
-
2003
- 2003-07-11 WO PCT/US2003/021655 patent/WO2004007020A2/en active Application Filing
- 2003-07-11 CA CA2491924A patent/CA2491924C/en not_active Expired - Fee Related
- 2003-07-11 MX MXPA05000565A patent/MXPA05000565A/en active IP Right Grant
- 2003-07-11 AU AU2003253877A patent/AU2003253877A1/en not_active Abandoned
- 2003-07-11 EP EP03764473A patent/EP1523370A1/en not_active Withdrawn
- 2003-07-11 JP JP2004521650A patent/JP2005532868A/en active Pending
- 2003-07-11 CN CN038166089A patent/CN1668359B/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3895639A (en) | 1971-09-07 | 1975-07-22 | Rodler Ing Hans | Apparatus for producing an interference signal at a selected location |
US4589423A (en) | 1980-04-02 | 1986-05-20 | Bsd Medical Corporation | Apparatus for creating hyperthermia in tissue |
US5251645A (en) | 1991-06-26 | 1993-10-12 | Massachusetts Institute Of Technology | Adaptive nulling hyperthermia array |
US5441532A (en) | 1991-06-26 | 1995-08-15 | Massachusetts Institute Of Technology | Adaptive focusing and nulling hyperthermia annular and monopole phased array applicators |
US5540737A (en) | 1991-06-26 | 1996-07-30 | Massachusetts Institute Of Technology | Minimally invasive monopole phased array hyperthermia applicators and method for treating breast carcinomas |
US5810888A (en) | 1997-06-26 | 1998-09-22 | Massachusetts Institute Of Technology | Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery |
US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
Non-Patent Citations (3)
Title |
---|
"Methods of External Hyperthermic Heating", 1990, SPRINGER VERLAG, article "Chou formulation", pages: 11 |
J.J. W. LAGENDIJK; P. NILSSON: "Hyperthermia Dough: A Fat and Bone Equivalent Phantom to Test Microwave/Radiofrequency Hyperthermia Heating Systems", PHYSICS IN MEDICINE AND BIOLOGY, vol. 30, no. 7, 1985, pages 709 - 712, XP020022956, DOI: doi:10.1088/0031-9155/30/7/011 |
See also references of EP1523370A1 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1539298A1 (en) * | 2002-07-16 | 2005-06-15 | Celsion Corporation | Method for improved safety in externally focused microwave thermotherapy for treating breast cancer |
EP3628251A1 (en) * | 2018-09-28 | 2020-04-01 | Koninklijke Philips N.V. | Ablation therapy planning system |
WO2020064659A1 (en) * | 2018-09-28 | 2020-04-02 | Koninklijke Philips N.V. | Ablation therapy planning system |
Also Published As
Publication number | Publication date |
---|---|
CN1668359B (en) | 2010-04-28 |
US20020193849A1 (en) | 2002-12-19 |
AU2003253877A1 (en) | 2004-02-02 |
MXPA05000565A (en) | 2005-04-28 |
EP1523370A1 (en) | 2005-04-20 |
JP2005532868A (en) | 2005-11-04 |
CN1668359A (en) | 2005-09-14 |
US6690976B2 (en) | 2004-02-10 |
CA2491924C (en) | 2014-09-09 |
CA2491924A1 (en) | 2004-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2491924C (en) | Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs | |
CA2492627C (en) | Method for improved safety in externally focused microwave thermotherapy for treating breast cancer | |
EP1581145B1 (en) | Thermotherapy apparatus for treatment and prevention of cancer in male and female patients and cosmetic ablation of tissue | |
CA2377248C (en) | Method and apparatus for treating breast lesions using microwaves | |
US6477426B1 (en) | System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumors | |
Fenn | An adaptive microwave phased array for targeted heating of deep tumours in intact breast: animal study results | |
CA2408627C (en) | System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumors | |
US20200146740A1 (en) | Thermodilatation and Thermocompression to Facilitate Targeted Cluster Tissue Ablation and Immune Response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 01981/KOLNP/2004 Country of ref document: IN Ref document number: 1981/KOLNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004521650 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2491924 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Country of ref document: MX Ref document number: PA/a/2005/000565 Ref document number: 20038166089 Country of ref document: CN |
|
REEP | Request for entry into the european phase |
Ref document number: 2003764473 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003764473 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003764473 Country of ref document: EP |